https://www.selleckchem.com/pr....oducts/cd38-inhibito
The ulcer residual ratios were 24.3±14.2%, 17.0±12.1%, and 21.0±13.8% in the PPI alone, PPI+rebamipide, and H2RA+rebamipide groups, respectively (P=0.048). PPI+rebamipide was more effective in reducing the ulcer residual ratio after ESD. There was no statistical difference in ulcer stage and delayed bleeding after ESD among the groups. These findings showed that PPI+rebamipide had limited benefits after ESD. PPI + rebamipide was more effective in reducing the ulcer residual ratio after ESD. There was no statistical difference i
Like
Comment
Share
